Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 3
1998 9
1999 1
2000 4
2001 6
2002 6
2003 4
2004 1
2005 7
2006 2
2007 11
2008 7
2009 8
2010 9
2011 2
2012 6
2013 7
2014 3
2015 4
2016 6
2017 13
2018 6
2019 6
2020 15
2021 10
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

153 results
Results by year
Filters applied: . Clear all
Page 1
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Fennell D, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Pairon JC, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Cardillo G, Putora PM. Scherpereel A, et al. Among authors: mutti l. Eur Respir J. 2020 Jun 11;55(6):1900953. doi: 10.1183/13993003.00953-2019. Print 2020 Jun. Eur Respir J. 2020. PMID: 32451346 Free article.
A Glimpse in the Future of Malignant Mesothelioma Treatment.
Pezzicoli G, Rizzo M, Perrone M, Minei S, Mutti L, Porta C. Pezzicoli G, et al. Among authors: mutti l. Front Pharmacol. 2021 Dec 15;12:809337. doi: 10.3389/fphar.2021.809337. eCollection 2021. Front Pharmacol. 2021. PMID: 34975505 Free PMC article. Review.
Anti-CTLA-4 therapy for malignant mesothelioma.
Guazzelli A, Bakker E, Krstic-Demonacos M, Lisanti MP, Sotgia F, Mutti L. Guazzelli A, et al. Among authors: mutti l. Immunotherapy. 2017 Mar;9(3):273-280. doi: 10.2217/imt-2016-0123. Immunotherapy. 2017. PMID: 28231719 Free article. Review.
Immunotherapy advances for mesothelioma treatment.
Bakker E, Guazzelli A, Ashtiani F, Demonacos C, Krstic-Demonacos M, Mutti L. Bakker E, et al. Among authors: mutti l. Expert Rev Anticancer Ther. 2017 Sep;17(9):799-814. doi: 10.1080/14737140.2017.1358091. Epub 2017 Jul 31. Expert Rev Anticancer Ther. 2017. PMID: 28724330 Free article. Review.
Is There Already a Need of Reckoning on Cancer Immunotherapy?
Correale P, Pentimalli F, Baglio G, Krstic-Demonacos M, Saladino RE, Giordano A, Mutti L. Correale P, et al. Among authors: mutti l. Front Pharmacol. 2021 Mar 26;12:638279. doi: 10.3389/fphar.2021.638279. eCollection 2021. Front Pharmacol. 2021. PMID: 33841155 Free PMC article. No abstract available.
Tumour Treating Fields for mesothelioma.
Barbarino M, Bottaro M, Luzzi L, Giordano A, Mutti L. Barbarino M, et al. Among authors: mutti l. Lancet Oncol. 2020 Jan;21(1):e8. doi: 10.1016/S1470-2045(19)30829-0. Lancet Oncol. 2020. PMID: 31908312 No abstract available.
Targeting hypoxic response for cancer therapy.
Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, Landi S. Paolicchi E, et al. Among authors: mutti l. Oncotarget. 2016 Mar 22;7(12):13464-78. doi: 10.18632/oncotarget.7229. Oncotarget. 2016. PMID: 26859576 Free PMC article. Review.
Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Mutti L, et al. J Thorac Oncol. 2018 Sep;13(9):1269-1283. doi: 10.1016/j.jtho.2018.06.011. J Thorac Oncol. 2018. PMID: 29966799 Free PMC article. Review.
Tremelimumab for the treatment of malignant mesothelioma.
Guazzelli A, Hussain M, Krstic-Demonacos M, Mutti L. Guazzelli A, et al. Among authors: mutti l. Expert Opin Biol Ther. 2015;15(12):1819-29. doi: 10.1517/14712598.2015.1116515. Expert Opin Biol Ther. 2015. PMID: 26560442 Review.
153 results